We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+39.15%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$831M
AUM Growth
+$203M
Cap. Flow
-$333M
Cap. Flow %
-40.1%
Top 10 Hldgs %
41.06%
Holding
181
New
59
Increased
25
Reduced
46
Closed
41

Top Buys

Rank Stock Value
1
RCKT icon
Rocket Pharmaceuticals
RCKT
+$11.9M
2
AKRO
Akero Therapeutics
AKRO
+$9.31M
3
TARS icon
Tarsus Pharmaceuticals
TARS
+$9.18M
4
CPRX
Catalyst Pharmaceutical
CPRX
+$6.77M
5
IMVT icon
Immunovant
IMVT
+$6.73M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$11.5M
2
INSM icon
Insmed
INSM
+$7.55M
3
IDYA icon
IDEAYA Biosciences
IDYA
+$6.95M
4
BHVN icon
Biohaven
BHVN
+$6.68M
5
BMEA icon
Biomea Fusion
BMEA
+$6.06M

Sector Composition

Rank Sector Weight
1 Healthcare 31.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RCUS icon
51
Arcus Biosciences
RCUS
$3.55B
$4.58M 0.55%
254,876
-25,124
-9% -$505K
VTYX
52
PUT
DELISTED
Ventyx Biosciences
VTYX
$4.28M 0.52%
1,233
-372,867
-100% -$12.9M
SWTX
53
DELISTED
SpringWorks Therapeutics
SWTX
$4.12M 0.5%
+178,360
New +$4.88M
ACRS icon
54
PUT
Aclaris Therapeutics
ACRS
$726M
$4.08M 0.49%
5,955
-790,345
-99% -$6.75M
REPL icon
55
CALL
Replimune Group
REPL
$941M
$3.98M 0.48%
2,325
-225,975
-99% -$4.44M
INSM icon
56
Insmed
INSM
$21.4B
$3.91M 0.47%
154,900
-330,100
-68% -$7.55M
PRAX icon
57
Praxis Precision Medicines
PRAX
$8.58B
$3.85M 0.46%
+150,000
New +$2.84M
ITOS
58
DELISTED
iTeos Therapeutics
ITOS
$3.79M 0.46%
+346,471
New +$4.43M
AMLX icon
59
CALL
Amylyx Pharmaceuticals
AMLX
$2.26B
$3.78M 0.45%
+2,065
New +$43.7K
SNDX icon
60
CALL
Syndax Pharmaceuticals
SNDX
$1.69B
$3.63M 0.44%
+2,500
New +$47.3K
EYPT icon
61
PUT
EyePoint Inc
EYPT
$1.03B
$3.59M 0.43%
+4,487
New +$49.2K
ITOS
62
CALL
DELISTED
iTeos Therapeutics
ITOS
$3.35M 0.4%
+3,056
New +$39.1K
CBAY
63
CALL
DELISTED
Cymabay Therapeutics
CBAY
$3.32M 0.4%
+2,230
New +$29.6K
CHRS icon
64
Coherus Oncology
CHRS
$217M
$3.24M 0.39%
+865,787
New +$4M
VERV
65
PUT
DELISTED
Verve Therapeutics
VERV
$3.2M 0.38%
+2,413
New +$38.9K
RCKT icon
66
CALL
Rocket Pharmaceuticals
RCKT
$340M
$3.07M 0.37%
+1,500
New +$27.3K
LBPH
67
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
$2.86M 0.34%
514,101
+9,848
+2% +$63.4K
ATXS
68
DELISTED
Astria Therapeutics
ATXS
$2.8M 0.34%
374,807
-204,583
-35% -$1.74M
BHVN icon
69
Biohaven
BHVN
$2.03B
$2.76M 0.33%
106,138
-321,279
-75% -$6.68M
LRMR icon
70
Larimar Therapeutics
LRMR
$397M
$2.7M 0.32%
+682,868
New +$2.58M
CLDX icon
71
PUT
Celldex Therapeutics
CLDX
$2.99B
$2.67M 0.32%
+971
New +$30.4K
VERV
72
CALL
DELISTED
Verve Therapeutics
VERV
$2.65M 0.32%
+2,000
New +$32.2K
ACRS icon
73
CALL
Aclaris Therapeutics
ACRS
$726M
$2.49M 0.3%
+3,637
New +$31.1K
RVPH
74
CALL
DELISTED
REVIVA PHARMA HLDGS INC
RVPH
$2.49M 0.3%
+255
New +$23.8K
DYN icon
75
CALL
Dyne Therapeutics
DYN
$4.7B
$2.44M 0.29%
+2,726
New +$29.4K
1 2
3
4 5

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q3 2023 Portfolio in Review

As of Q3 2023, Ikarian Capital held 181 positions worth $831M, up 32% from $628M the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Ikarian Capital withdrew a net $333M in Q3 2023, closing 41 positions and reducing 46 holdings. Its most notable exit was Merck, an estimated $11.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 32% of assets, down from 44% a quarter earlier.

Against the trend, Ikarian Capital opened a new position in Rocket Pharmaceuticals worth $13.4M.

  • Ikarian Capital's largest Q3 2023 buy was Rocket Pharmaceuticals: 654,726 shares worth $13.4M.
  • Ikarian Capital added most to Crinetics Pharmaceuticals in Q3 2023, an estimated $6.55M increase.
  • Ikarian Capital's biggest Q3 2023 reduction was Insmed, cutting an estimated $7.55M.
  • Ikarian Capital fully exited Merck in Q3 2023, selling an estimated $11.5M.
  • Ikarian Capital's ten largest holdings make up 41% of its $831M portfolio in Q3 2023.
  • Ikarian Capital opened 59 new positions and closed 41 in Q3 2023.
  • Ikarian Capital's portfolio value rose 32% quarter-over-quarter to $831M.

Based on Ikarian Capital's 13F filing for Q3 2023, filed 14 Nov 2023.